Departments of Pulmonary Medicine.
Radiodiagnosis.
J Bronchology Interv Pulmonol. 2020 Oct;27(4):286-293. doi: 10.1097/LBR.0000000000000672.
Tracheobronchial stenting either alone or with esophageal stenting is often required for symptom palliation in obstructive or fistulous lesions of the airway due to esophageal cancer. There is limited evidence regarding dual stenting for lesions near the carina due to esophageal cancer. Hence, this study aims to evaluate the technical feasibility, outcomes, and complications of preplanned dual stenting in these patients.
This is a prospective observational study carried out over a period of 4 years (January 2015 to July 2019). All patients undergoing dual stenting in the airway and esophagus with obstructive or fistulous lesions near the carina were included. The esophageal stent was placed within 24 hours. Prestenting and poststenting symptoms were compared using a symptom-based visual analog scale, Hugh Jones dyspnea scale and dysphagia scale.
Twenty-nine patients (20 males; mean±SD age, 55.3±12.2 y) underwent dual stenting. Twenty-four patients had central airway obstruction due to: infiltration in 20 (69%) and external compression in 4 (13.7%), respectively. Five (17.3%) patients had tracheoesophageal fistula with no airway obstruction. In 80% of the patients (n=23), silicone stents were placed. There was significant improvement in both dyspnea and dysphagia after dual stenting (P<0.001). Mucus plugging, lower respiratory infection, and granulation tissue were the main complications. Median survival after dual stent was 97 days (range, 17 to 297 d).
Dual stenting within the airway and the esophagus is a safe and viable option for palliative relief of symptoms in patients with advanced esophageal cancer.
由于食管癌导致的气道阻塞或瘘管病变,常需要单独或联合进行气管-支气管支架置入或食管支架置入以缓解症状。对于因食管癌导致隆嵴附近病变的双重支架置入,相关证据有限。因此,本研究旨在评估这些患者预先计划的双重支架置入的技术可行性、结果和并发症。
这是一项前瞻性观察研究,在 4 年期间(2015 年 1 月至 2019 年 7 月)进行。所有因气道和食管阻塞或瘘管病变而在隆嵴附近行双重支架置入的患者均被纳入研究。食管支架在 24 小时内放置。使用基于症状的视觉模拟量表、Hugh Jones 呼吸困难量表和吞咽困难量表比较支架置入前和置入后的症状。
29 例患者(20 例男性;平均年龄±标准差,55.3±12.2 岁)接受了双重支架置入。24 例患者因中央气道阻塞而接受治疗:浸润 20 例(69%),外压 4 例(13.7%)。5 例(17.3%)患者存在气管-食管瘘但无气道阻塞。80%(n=23)的患者使用了硅酮支架。双重支架置入后呼吸困难和吞咽困难均有显著改善(P<0.001)。主要并发症包括黏液嵌塞、下呼吸道感染和肉芽组织。双重支架置入后中位生存时间为 97 天(范围,17~297 天)。
气道和食管内双重支架置入是缓解晚期食管癌患者症状的安全可行选择。